Barclays raised the firm’s price target on Quest Diagnostics (DGX) to $195 from $190 and keeps an Equal Weight rating on the shares post the Q3 report. The company reported “another solid print,” the analyst tells investors in a research note. The firm views the post-earnings share selloff as a function of investor positioning given the strength in core tools names and improving sentiment versus moving away from the more defensive labs.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics Reports Strong Q3 2025 Results
- Quest Diagnostics: Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
- Quest Diagnostics price target raised to $215 from $200 at Jefferies
- Quest Diagnostics price target raised to $210 from $203 at Leerink
- Morning Movers: General Motors and RTX higher following Q3 reports